Treatment of neuroendocrine liver metastases: evolution over 3 decades
Research type
Research Study
Full title
Treatment of neuroendocrine liver metastases: a retrospective review of evolution over 3 decades of clinical practice
IRAS ID
317371
Contact name
Andrea Frilling
Contact email
Sponsor organisation
Imperial College London
Duration of Study in the UK
0 years, 1 months, 28 days
Research summary
Neuroendocrine tumours are uncommon cancers, but they are very difficult to treat. One reason for this is their high rate of spread (metastasis) to the liver. Effective treatment of these liver metastases is a major part of treating patients. Over the last 20-30 years, several new treatments have become available for neuroendocrine liver metastases, such as hormonal medications, targeted radiotherapy, and interventional treatments that target tumours via the blood vessels nearby. In this study, we seek to explore how treatment for these neuroendocrine liver metastases has evolved over the last 3 decades, and what their effects have been on outcomes. We seek to pool the experience from one specialist centre in the United Kingdom (Imperial College) and others from Germany, and gain insight into this. This study will use routinely collected clinical data, appropriately anonymised at all stages.
REC name
South Central - Berkshire B Research Ethics Committee
REC reference
23/SC/0028
Date of REC Opinion
10 Jan 2023
REC opinion
Favourable Opinion